Grossmont Center for Clinical Research

La Mesa, California 92008

0 studies enrolling now · 25 studies all time

What they study most

Aneuploidy, Cervical Intraepithelial Neoplasia, Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial, Contraception, Diarrhea Predominant Irritable Bowel Syndrome, Diarrhea-predominant Irritable Bowel Syndrome, Down Syndrome, Edwards Syndrome, Episodic Migraine, Hot Flashes, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome With Diarrhea (IBS-D)

Studies at this site

• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids — Stopped early
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause — Completed
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) — Stopped early
• Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery — Completed
• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) — Completed
• An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). — Completed
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome — Completed
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) — Completed
• A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms — Completed
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study — Completed
• An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ — Stopped early
• Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) — Completed
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine — Completed
• Vaginal Infection Study — Completed
• Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker — Completed